a randomised, double-blind, controlled vaccine efficacy trial of dnamva me-trap against malaria infection in gambian adults随机,双盲控制疫苗效力试验dnamva me-trap对抗疟疾感染冈比亚的成年人.pdfVIP

下载本文档

1
0
约7.18万字
约 9页
2017-09-05 发布于上海
举报
版权申诉

a randomised, double-blind, controlled vaccine efficacy trial of dnamva me-trap against malaria infection in gambian adults随机,双盲控制疫苗效力试验dnamva me-trap对抗疟疾感染冈比亚的成年人.pdf

1、本文档共9页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

a randomised, double-blind, controlled vaccine efficacy trial of dnamva me-trap against malaria infection in gambian adults随机,双盲控制疫苗效力试验dnamva me-trap对抗疟疾感染冈比亚的成年人

Open access, freely available online PLoS MEDICINE A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults 1,2* 1 1 1 2 1 Vasee S. Moorthy , Egeruan B. Imoukhuede , Paul Milligan , Kalifa Bojang , Sheila Keating , Pauline Kaye , Margaret Pinder1 3 1 4 2,3 , Sarah C. Gilbert , Gijs Walraven , Brian M. Greenwood , Adrian V. S. Hill 1 Medical Research Council Laboratories, Banjul, Gambia, 2 Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom, 3 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 4 London School of Hygiene and Tropical Medicine, London, United Kingdom Competing Interests: VSM, EBI, A B S T R A C T PM, KB, SK, PK, MP, SCG, GW, and BMG have declared that no com- peting interests exist. AVSH is a co-founder and equity holder in Background Oxxon Therapeutics, a company developing prime-boost therapeu- Many malaria vaccines are currently in development, although very few have been evaluated tic vaccines. for efficacy in the field. Plasmodium falciparum multiple epitope (ME)– thrombospondin-related Author Contributions: See Ac- adhesion protein (TRAP) candidate vaccines are designed to potently induce effector T cells knowledgments. and so are a departure from earlier malaria vaccines evaluated in the field in terms of their